Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options

References

• European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018. Aug;69(2):461-511.
   Google Scholar
• Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14(2):122–132.
   PubMed Web of Science ®Google Scholar
• Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70–86.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Hepatitis: HCV variability, the immune system and resistance to antiviral drugs. Nat Rev Gastroenterol Hepatol. 2009;6(7):383–385.
   PubMed Web of Science ®Google Scholar
• Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Updat. 2018;37:17–39.
   PubMed Web of Science ®Google Scholar
• Cento V, Chevaliez S, Perno CF. Resistance to direct-acting antiviral agents: clinical utility and significance. Curr Opin HIV AIDS. 2015;10(5):381–389.
   PubMed Web of Science ®Google Scholar
• Ceccherini Silberstein F, Di Maio VC, Aragri M, et al. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology. 2016;63(3):1058–1059.
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504.
   PubMed Web of Science ®Google Scholar
• Wyles DL. Resistance to DAAs: when to look and when it matters. Curr HIV/AIDS Rep. 2017;14(6):229–237.
   PubMed Web of Science ®Google Scholar
• McGivern DR, Masaki T, Williford S, et al. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology. 2014;147(2):453–462 e457.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66(5):910–918.
   PubMed Web of Science ®Google Scholar
• Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;61:5.
   Web of Science ®Google Scholar
• Wyles D, Mangia A, Cheng W, et al. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir Ther. 2017;23:229–238.
   Google Scholar
• Yoshimi S, Imamura M, Murakami E, et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015;87(11):1913–1920.
   PubMed Web of Science ®Google Scholar
• Krishnan P, Schnell G, Tripathi R, et al. Analysis of hepatitis C virus genotype 1b resistance variants in japanese patients treated with paritaprevir-ritonavir and ombitasvir. Antimicrob Agents Chemother. 2016;60(2):1106–1113.
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Dvory-Sobol H, Doehle BP, et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother. 2016;60(9):5368–5378.
   PubMed Web of Science ®Google Scholar
• Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56(6):3359–3368.
   PubMed Web of Science ®Google Scholar
• Di Maio VC, Cento V, Lenci I, et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37(4):514–528.
   PubMed Web of Science ®Google Scholar
• Donaldson EF, Harrington PR, O’Rear JJ, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015;61(1):56–65.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Metivier S, Nahass R, et al. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatol Commu. 2017;1(6):538–549.
   PubMed Web of Science ®Google Scholar
• McPhee F, Hernandez D, Zhou N, et al. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir. Antivir Ther. 2018;23(1):53–66.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NS5A resistance-associated variants (RASs) on the Efficacy Of Elbasvir/Grazoprevir (EBR/GZR) against GT1a infection - 16 weeks vs 12 weeks. Hepatology. 2015;62:1393A–1394A.
   Web of Science ®Google Scholar
• Zeuzem S, Rockstroh J, Kwo P, et al. Predictors of response to grazoprevir/elbasvir among HCV genotype 1 (GT1)–infected patients: integrated analysis of phase 2–3 trials. Hepatology. 2015;62:554A–555A.
   Web of Science ®Google Scholar
• Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–1097.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075–1086.
   PubMed Web of Science ®Google Scholar
• Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62(1):32–36.
   PubMed Web of Science ®Google Scholar
• Foster GR, Agarwal K, Cramp ME, et al. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. Hepatology. 2018;67:2113–2126.
   PubMed Web of Science ®Google Scholar
• Bourliere M, Gordon SC, Flamm SL, et al. sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–2146.
   PubMed Web of Science ®Google Scholar
• Poordad F, Bennett M, Sepe TE, et al. 2016. Ombitasvir/Paritaprevir/R, dasabuvir and sofosbuvir treatment of patients with genotype 1-infection who failed a prior course of DAA therapy: the Quartz-I study. Gastroenterology. 2016; April Volume 150, Issue 4, Supplement 1, Page S1040.
   Google Scholar
• Wyles D, Wedemeyer H, Ben-Ari Z, et al. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. Hepatology. 2017;66(6):1794–1804.
   PubMed Web of Science ®Google Scholar
• Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66(2):389–397.
   PubMed Web of Science ®Google Scholar
• Wang GP, Terrault N, Reeves JD, et al. Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep. 2018;8(1):3199.
   PubMedGoogle Scholar
• Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954.
   PubMed Web of Science ®Google Scholar
• Wyles D, Weiland O, Yao B, et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2018;68:S23–24.
   Google Scholar
• Craxi A, Perno CF, Vigano M, et al. From current status to optimization of HCV treatment: recommendations from an expert panel. Dig Liver Dis. 2016 Sep;48(9):995-1005.
   Google Scholar
• Vigano M, Perno CF, Craxi A, et al. Treatment of hepatitis C virus infection in Italy: a consensus report from an expert panel. Dig Liver Dis. 2017;49(7):731–741.
   PubMedGoogle Scholar
• Fourati S, Pawlotsky JM. Virologic tools for HCV drug resistance testing. Viruses. 2015;7(12):6346–6359.
   PubMed Web of Science ®Google Scholar
• Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010;11(1):31–46.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(3):501-+.
   PubMed Web of Science ®Google Scholar
• Loggi E, Galli S, Vitale G, et al. Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods. PLoS One. 2017;12(11):e0187755.
   PubMed Web of Science ®Google Scholar
• Aghemo A, Degasperi E, De Nicola S, et al. Quantification of core antigen monitors efficacy of direct-acting antiviral agents in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepato. 2016;14:1331–1336.
   PubMed Web of Science ®Google Scholar
• Chevaliez S, Feld J, Cheng K, et al. Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. Antivir Ther. 2016;23:211–217.
   Google Scholar